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a b s t r a c t 
The primary choice among treatment options for liver malignancies is surgery. However, if 
surgery cannot be performed, Stereotactic body radiotherapy (SBRT) may be effective. 99m- 
technetium galactosyl human serum albumin (GSA) single-photon emission computed to- 
mography (SPECT) imaging is useful for the assessment of liver function before surgery. We 
report the case of a 77-year-old man who had undergone SBRT for hepatocellular carcinoma 
of the left lobe of the liver 2 years previously. Follow-up revealed a 15-mm hepatocellular 
carcinoma at the edge of the right lobe of the liver. 99m-technetium GSA SPECT was per- 
formed before SBRT to confirm that there was no accumulation in the left lobe and to ensure 
that there was good function of the right lobe. Three months after SBRT, the tumor had re- 
sponded, and decreases in GSA accumulation were observed in line with the radiation beam. 
Because hepatocellular carcinoma often relapses, it is important to assess the anatomic site 
of liver dysfunction before and after radiation. This case demonstrates that 99m-technetium 
GSA SPECT is useful for this purpose. 
© 2019 The Authors. Published by Elsevier Inc. on behalf of University of Washington. 
This is an open access article under the CC BY-NC-ND license. 
( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 
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 Hepatectomy is associated with the best outcomes [1–4] . How-
ever, patients requiring extensive resection or who have liver
disease with compromised hepatocellular function are at high
risk of developing postoperative liver failure. 
Stereotactic body radiotherapy (SBRT) is increasingly avail-
able and is another option for treatment of localized liver tu-
mors. However, just as with surgery, it is important to predict
hepatic reserve before and after treatment. An accurate as-
sessment of liver reserve is intended to reduce the risk of liver
failure after irradiation. 
One way to measure liver function rapidly and noninva-
sively is by measuring the clearance of indocyanine green
(ICG) [4] . ICG elimination, expressed as the ICG plasma dis-
appearance rate or the retention rate at 15 minutes (ICG-
R15), assesses relative ICG concentration changes. Another
technique uses 99m-technetium galactosyl human serum al-
bumin (GSA)-single-photon emission computed tomography
(SPECT). Although this has been used primarily for preop-
erative evaluation of hepatocellular carcinoma (HCC) to be
treated surgically, it could also be used for patients who will
undergo targeted SBRT [5–10] . We report a case in which GSA
was used to assess functional liver reserve both before and af-
ter SBRT, comparing it with the results of ICG clearance test-
ing. 
Case report 
A 77-year-old man had been diagnosed with chronic hepati-
tis C about 20 years previously. In 2016, he was treated withFig. 1 – Initial radiotherapy for left lobe of the liver. (A) Radiothera
fractions in 2016. Dose volume histogram; left lower image. Red 
Purple line: whole liver. (B) 99m-Tc GSA–SPECT/CT image after S
where (arrow) the tumor had been treated. (C) No evidence of rec
galactosyl human serum albumin. transarterial chemoembolization and SBRT (40 Gy in 10 frac-
tions) for HCC in the left lobe of his liver ( Fig. 1 A). No recur-
rence was seen over the next 2 years. There was no accumu-
lation of GSA in images of the left hepatic lobe ( Fig. 1 B), and
contrast-enhanced CT showed no tumor ( Fig. 1 C). 
In 2018, a 15-mm HCC was seen in the right hepatic
lobe. Laboratory data were as follows: Hemoglobin, White
blood cells, platelet, alanine aminotransferase (ALT), aspartate
aminotransferase (AST), alkaline phosphatase and bilirubin,
albumin, bilirubin, and prothrombin time were within nor-
mal limits before and after SBRT. Tumor marker α-fetoprotein
(AFP) was maintained below 10 ng/mL; however, the amount
of protein induced by vitamin K absence or antagonist-2
(PIVKA-2) was increasing (395 AU/mL), and thus, SBRT was
planned. 
Because the tumor was close to the kidney, radiofrequency
ablation was considered too dangerous, and radiotherapy was
therefore scheduled ( Fig. 2 ). The pretreatment ICG-R15 value
was 14%. We treated the right hepatic HCC with SBRT (42 Gy
in 4 fractions) ( Fig. 3 A). Three months later, the ICG-R15 value
had slightly deteriorated to 18%. Irradiated tumor disappeared
( Fig. 3 B). GSA imaging at that time showed decreased accumu-
lation along the beam path ( Fig. 3 C,D). 
With a cutoff value of counts of 150 in the pre- and
post-treatment GSA images, the volume of accumulation in
the liver showed a 40-cc drop from 1280 to 1240 cc. The
volume of the liver overall did not otherwise change (1333
and 1322 cc.) The tumor marker PIVKA-2 was decreased
(54 AU/mL). py planning to treat HCC in the left lobe using 40 Gy/10 
line: planning target volume. Green line: stomach wall. 
BRT showing no accumulation in the left lobe of the liver 
urrence is seen on contrast-enhanced CT (arrow). GSA, 
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Fig. 2 – Two years after initial radiotherapy for left lobe of the liver. (A) Contrast-enhanced CT showing a 15-mm tumor at the 
edge of the right lobe of the liver (arrow). (B) Diffusion-weighed MR image shows a tumor with a reduced apparent diffusion 
coefficient at the edge of the right lobe (arrow). (C) There is no abnormality around the tumor in a 99m-Tc GSA–SPECT/CT 
Image before SBRT. GSA, galactosyl human serum albumin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Discussion 
CT is the modality commonly used in the planning of hepa-
tectomy. Although quantitative evaluation using GSA as a nu-
clear medicine technique has been used, it was thought insuf-
ficient as a simulation before surgery [4] . However, the use of
SPECT/CT has allowed prehepatectomy evaluation that gives
both functional and spatial information, providing a more
useful assessment than CT alone [5–8] . What is of particular
interest in our case is the use of 99m-Tc GSA–SPECT/CT before
SBRT, not surgical resection. 
Evaluation of liver function by contrast-enhanced CT 
Contrast-enhanced CT is widely used in prehepatectomy sim-
ulations because it provides anatomical information neces-
sary for planning lines of separation such as along veins
and portal veins. Generally, in the simulation by contrast-
enhanced CT, measurements include the total liver volume
and the volume of the area to be resected. The ratio of the
volume of the resected area to the total liver volume (volume
resection rate) is then calculated. However, the volume assess-
ment alone cannot reflect impairment of liver function at the
histologic level. The distribution of abnormal function may be
uneven in the presence of chronic hepatitis or when tumors
involve vessels. Similarly, when planning ablation with SBRT,
the volume ablation rate may be under- or overestimated
by CT imaging alone. Therefore, in cases of likely functionalheterogeneity, pre-SBRT simulation requires the addition of
functional assessment. 
Utility of 99m-Tc GSA scintigraphy 
GSA is a synthetic glycoprotein that exhibits the same in
vivo behavior as the asialoglycoprotein expressed on the sinu-
soidal surface of normal hepatocytes. GSA specifically binds
to the asialoglycoprotein receptor. Therefore, GSA can reflect
the number and function of normal hepatocytes. In terms of
quantitative evaluation by scintigraphy alone, the HH15 (clear-
ance index) and LHL15 (receptor index), calculated from dy-
namic study by planar image, are generally used. HH15 and
LHL15 are simple and reproducible indicators useful for eval-
uating the reserve capacity of the entire liver. However, the
planar image lacks anatomical information. Also, it is not pos-
sible to correct for the influence of the attenuation of accumu-
lation due to the distance from the body surface. Therefore,
liver function may be over- or underestimated. 
The introduction of SPECT has partially addressed this
problem. The use of SPECT images gives more anatomical
information than planar images [5 ,8 ,10] . However, because
SPECT still does not provide adequate anatomical informa-
tion, particularly about blood vessels, only a rough estimate
can be made for planning resection lines. 
The Chang method has been used to correct for attenu-
ation in order to improve the quantitative results of SPECT
images. However, the liver is not uniform, and its relation-
ship with surrounding organs and bones is more complicated
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Fig. 3 – Three month after treatment of recurrence in right lobe of the liver. (A) SBRT beam planning. Red line defines the 
planning target volume. Yellow indicates 95% coverage of the prescribed dose (42 Gy/4 fractions). Dose volume histogram. 
Red line: planning target volume. Green line: right kidney. Pink line: whole liver. (B) Diffusion-weighed MR image. There is 
no abnormal intensity in the whole liver and irradiated tumor was disappeared (arrow). (C) A defect in accumulation in line 
with the radiation beam is observed in the 99m-Tc GSA–SPECT/CT Image. (D) Image obtained by subtracting GSA 
accumulation after radiation treatment from GSA before radiotherapy. The subtracted area is shown in blue. GSA, galactosyl 
human serum albumin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 than that of other structures such as the brain. Therefore, the
Chang method is not sufficient for attenuation correction in
99m-Tc GSA–SPECT images. 
Method for using 99m-Tc GSA–SPECT for functional image 
prior to liver SBRT 
There are a few reports of scintigraphy used for evaluation of
liver reserve before radiotherapy. Fukugawa et al reported that
gadolinium ethoxybenzyl diethlenetriamine pentaacetic acid
(Gadolinium-EOB-DTPA)–enhanced MRI was useful for pre-
dicting hepatic function in cases where 3-dimensional radio-
therapy was used. The percentage of the whole liver volume
receiving a dose of more than 30–40 Gy is a potential candi-
date optimal DVH parameter for this fractionation schedule
[6] . They concluded that in patients with HCC who undergo
3D-CRT in 15 fractions, the threshold dose for focal liver reac-
tion is nearly 35 Gy. In contrast, we did not perform MRI. One
reason is that the value of PIVKA-2 decreased in blood tests.
No decrease was observed in liver function in the ICG test. In
our hospital, screening is performed by echo after 6 months
of treatment or when signs of recurrence appear. Contrast-
enhanced MRI or contrast-enhanced CT is performed when
a tumorous lesion is found in the echo. 
Fukugawa et al evaluated using 3-dimensional RT; in con-
trast, we performed SBRT, and the relationship between MRIand GSA might be different from that evaluated by Fukugawa
et al. In the case of SBRT, because the high dose was irradi-
ated, the liver function was locally abolished only at the site
from where the beam passed, as shown in Figure 3 . The same
phenomenon occurred as when the left lobe of the liver was
irradiated 2 years ago ( Fig. 1 ). In our hospital, a session is cur-
rently being conducted to evaluate the relationship between
MRI and GSA. 
Son et al reported on factors predicting a reduction in liver
function after helical tomotherapy [7] . An increase of at least
2 points in the Child–Pugh class score is a radiation dose-
limiting factor, and the nontarget normal liver receiving a dose
more than 15 Gy (V15 Gy) should be < 43.2% to reduce the
risk of the deterioration of hepatic function. In a retrospective
analysis of 12 patients Toya et al reported that previous treat-
ments significantly influenced the parametric discrepancy
between dose-function histogram and DVH. The use of dose-
function histogram may facilitate the detection of dosimet-
ric parameters for the precise prediction of radiation-induced
liver toxicity [8] . Dyk et al reported on the effect of high-dose
SBRT on liver function. Approximately one-quarter of patients
experience a decline in Child–Pugh class after high-dose liver
SBRT [9] . The V25 may be an important dosimetric parameter
predicting decline in liver function after treatment. A V25 >
32% was associated with a 42% incidence of Child–Pugh class
decline compared with 9% for V25 ≤ 32 ( P = .029). For primary
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 liver malignancies, a V25 > 36% was associated with a 4-fold
increase in the incidence of Child–Pugh class decline (60% vs
15%, P = 0.021). 
We subtracted the GSA count value after treatment from
the value before treatment and evaluated the region in which
treatment diminished liver function in a 3-dimensional im-
age ( Fig. 3 ). We think that creating this 3-dimensional image
is useful for beam planning with noncoplanar imaging. Specif-
ically, treatment can be planned to avoid as much as possible
passing the beam through the normal liver. Rather, the aim is
to pass it through a portion that is already nonfunctioning. 
The challenge is deciding the cutoff of the count value. We
are planning to accumulate more cases to develop a quanti-
tative method based not only on the liver structure but also
the body type and subcutaneous fat. The correlation between
the results of ICG tests and those of GSA imaging need to be
examined in more detail. 
In our patient, GSA was useful to assess the distribution
of hepatic reserve before and after SBRT. Additionally, the de-
crease in the GSA count value was similar to the decrease in
liver function indicated by the ICG test. Because HCC often
recurs, repeat treatment with irradiation may be necessary.
Functional imaging with GSA is a useful option for evaluating
liver reserve and for radiotherapy beam planning. 
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